The “Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Insight, 2021” drug pipeline has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in the Chronic obstructive pulmonary disease pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic obstructive pulmonary disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease Emerging Drugs Chapters
This segment of the Chronic obstructive pulmonary disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic obstructive pulmonary disease Emerging Drugs
- Itepekimab: Sanofi/ Regeneron
- Ensifentrine: Verona Pharma
- Tezepelumab: Amgen/ AstraZeneca
- BCT-197: Mereo Biopharma
Chronic obstructive pulmonary disease: Therapeutic Assessment
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
This segment of the report provides insights about the different Chronic obstructive pulmonary disease drugs segregated based on the following parameters that define the scope of the report, such as:
Major Players in Chronic obstructive pulmonary disease
There are approx. 60+ key companies are developing therapies for Chronic obstructive pulmonary disease. The companies which have their Chronic obstructive pulmonary disease drug candidates in the most advanced stage, i.e. Phase III include, Sanofi/ Regeneron.
Source: Businesswire